SEC Form 4Coverage since Aug 8, 2025Open-market trades only
$AORT insider trading
Over the last 12 months, Artivion insiders reported no purchases and 46 sales totaling $20.7M across SEC Form 4 filings. 11% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $20.7M 46 events
- Events · 12m
- 46 Form 4 filings, grouped
- Insiders · 12m
- 8 distinct reporters
- 10b5-1 share
- 11% of events, not dollars
Side
Price · $AORT · 3Mvia TradingView
Top insiders · 12m
Holloway Jean FSVP, General Counsel8× · $2.5M
Mackin James PPresident & CEO8× · $9.7M
Horton AmyVP, Chief Accounting Officer7× · $870K
Davis John EChief Commercial Officer7× · $1.7M
Stanton Marshall S.SVP, Clinical & MD Affair7× · $3.4M
All insider trades
50 of 52 events
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | GREEN ANDREW MSVP, Regulatory and Quality · O | ▼ Sale | 11,480 | $24.97 | $287K | -22.2% | — |
| Sep 3, 2026 | GREEN ANDREW MSVP, Regulatory and Quality · O | ▼ Sale | 8,003 | $27.03 | $216K | -13.4% | 2 tranches |
| Aug 19, 2026 | Mackin James PPresident & CEO · O | ▼ Sale | 70,000 | $28.96 | $2.0M | -7.4% | — |
| Aug 14, 2026 | GREEN ANDREW MSVP, Regulatory and Quality · O | ▼ Sale | 616 | $28.55 | $18K | -1% | — |
| Aug 14, 2026 | Berry Lance AEVP, COO, CFO & Treasurer · O | ▼ Sale | 715 | $28.55 | $20K | -0.3% | — |
| Aug 12, 2026 | Holloway Jean FSVP, General Counsel · O | ▼ Sale | 977 | $28.49 | $28K | -0.5% | — |
| Jun 11, 2026 | GREEN ANDREW MSVP, Regulatory and Quality · O | ▼ Sale | 44,001 | $20.7 | $911K | -42.2% | plan · 2 tranches |
| Mar 4, 2026 | Holloway Jean FSVP, General Counsel · O | ▼ Sale | 12,805 | $37.93 | $486K | -6.5% | 2 tranches |
| Mar 3, 2026 | Horton AmyVP, Chief Accounting Officer · O | ▼ Sale | 901 | $37.78 | $34K | -0.6% | — |
| Mar 3, 2026 | Stanton Marshall S.SVP, Clinical & MD Affair · O | ▼ Sale | 2,149 | $37.78 | $81K | -3.5% | — |
| Mar 3, 2026 | Davis John EChief Commercial Officer · O | ▼ Sale | 4,573 | $37.78 | $173K | -1.9% | — |
| Mar 3, 2026 | Berry Lance AEVP, COO, CFO & Treasurer · O | ▼ Sale | 6,316 | $37.78 | $239K | -2.9% | — |
| Mar 3, 2026 | Mackin James PPresident & CEO · O | ▼ Sale | 17,887 | $37.78 | $676K | -1.9% | — |
| Mar 2, 2026 | Horton AmyVP, Chief Accounting Officer · O | ▼ Sale | 641 | $38.02 | $24K | -0.5% | — |
| Mar 2, 2026 | Stanton Marshall S.SVP, Clinical & MD Affair · O | ▼ Sale | 1,513 | $38.02 | $58K | -3.6% | — |
| Mar 2, 2026 | Mackin James PPresident & CEO · O | ▼ Sale | 14,911 | $38.02 | $567K | -1.7% | — |
| Mar 2, 2026 | Holloway Jean FSVP, General Counsel · O | ▼ Sale | 2,183 | $38.02 | $83K | -1.3% | — |
| Mar 2, 2026 | Berry Lance AEVP, COO, CFO & Treasurer · O | ▼ Sale | 5,178 | $38.02 | $197K | -2.9% | — |
| Mar 2, 2026 | Davis John EChief Commercial Officer · O | ▼ Sale | 2,784 | $38.02 | $106K | -1.3% | — |
| Feb 24, 2026 | Horton AmyVP, Chief Accounting Officer · O | ▼ Sale | 2,561 | $36.97 | $95K | -2% | 2 tranches |
| Feb 24, 2026 | Stanton Marshall S.SVP, Clinical & MD Affair · O | ▼ Sale | 3,682 | $36.94 | $136K | -8.1% | 2 tranches |
| Feb 24, 2026 | Holloway Jean FSVP, General Counsel · O | ▼ Sale | 4,747 | $36.92 | $175K | -3% | 2 tranches |
| Feb 24, 2026 | Mackin James PPresident & CEO · O | ▼ Sale | 34,898 | $36.83 | $1.3M | -4.4% | 2 tranches |
| Feb 24, 2026 | Berry Lance AEVP, COO, CFO & Treasurer · O | ▼ Sale | 9,466 | $36.69 | $347K | -6.2% | 2 tranches |
| Feb 24, 2026 | Davis John EChief Commercial Officer · O | ▼ Sale | 5,848 | $36.92 | $216K | -3% | 2 tranches |
| Dec 15, 2025 | Davis John EChief Commercial Officer · O | ▼ Sale | 5,000 | $45.11 | $226K | -2.5% | — |
| Dec 8, 2025 | Horton AmyVP, Chief Accounting Officer · O | ▼ Sale | 4,572 | $44.42 | $203K | -3.4% | — |
| Dec 3, 2025 | Mackin James PPresident & CEO · O | ▼ Sale | 30,921 | $45.46 | $1.4M | -3.7% | plan |
| Dec 3, 2025 | Holloway Jean FSVP, General Counsel · O | ▼ Sale | 7,315 | $45.3 | $331K | -4.5% | 2 tranches |
| Dec 2, 2025 | Mackin James PPresident & CEO · O | ▼ Sale | 30,921 | $45.56 | $1.4M | -3.7% | plan |
| Nov 21, 2025 | Stanton Marshall S.SVP, Clinical & MD Affair · O | ▼ Sale | 47,376 | $45.04 | $2.1M | -51.4% | 4 tranches |
| Nov 20, 2025 | Stanton Marshall S.SVP, Clinical & MD Affair · O | ▼ Sale | 15,276 | $44.18 | $675K | -25.4% | 3 tranches |
| Nov 18, 2025 | Hoff Elizabeth AD | ▼ Sale | 4,200 | $45.1 | $189K | -13.4% | — |
| Nov 17, 2025 | Holloway Jean FSVP, General Counsel · O | ▼ Sale | 12,787 | $45.09 | $577K | -7.3% | plan · 2 tranches |
| Nov 17, 2025 | Davis John EChief Commercial Officer · O | ▼ Sale | 12,787 | $44.92 | $574K | -6% | plan · 2 tranches |
| Nov 17, 2025 | Horton AmyVP, Chief Accounting Officer · O | ▼ Sale | 6,000 | $45.73 | $274K | -4.2% | — |
| Nov 13, 2025 | Horton AmyVP, Chief Accounting Officer · O | ▼ Sale | 3,482 | $45.86 | $160K | -2.4% | — |
| Nov 13, 2025 | Davis John EChief Commercial Officer · O | ▼ Sale | 6,563 | $45.86 | $301K | -3.2% | — |
| Nov 13, 2025 | Mackin James PPresident & CEO · O | ▼ Sale | 34,210 | $45.86 | $1.6M | -4.1% | — |
| Nov 13, 2025 | Holloway Jean FSVP, General Counsel · O | ▼ Sale | 5,761 | $45.86 | $264K | -3.4% | — |
| Nov 13, 2025 | Stanton Marshall S.SVP, Clinical & MD Affair · O | ▼ Sale | 4,993 | $45.86 | $229K | -8.1% | — |
| Nov 11, 2025 | Holloway Jean FSVP, General Counsel · O | ▼ Sale | 12,960 | $45.82 | $594K | -7.1% | 2 tranches |
| Nov 10, 2025 | Mackin James PPresident & CEO · O | ▼ Sale | 17,580 | $44.62 | $784K | -2.1% | — |
| Nov 10, 2025 | Davis John EChief Commercial Officer · O | ▼ Sale | 3,373 | $44.62 | $150K | -1.6% | — |
| Nov 10, 2025 | Horton AmyVP, Chief Accounting Officer · O | ▼ Sale | 1,789 | $44.62 | $80K | -1.2% | — |
| Nov 10, 2025 | Stanton Marshall S.SVP, Clinical & MD Affair · O | ▼ Sale | 2,566 | $44.62 | $114K | -4% | — |
| Aug 27, 2025 | Stanton Marshall S.SVP, Clinical & MD Affair · O | ▼ Sale | 18,200 | $44.02 | $801K | -22.1% | — |
| Aug 25, 2025 | Holloway Jean FSVP, General Counsel · O | ▼ Sale | 10,000 | $44.37 | $444K | -5.5% | — |
| Aug 15, 2025 | Mackin James PPresident & CEO · O | ▼ Sale | 12,500 | $42.32 | $529K | -1.4% | — |
| Aug 12, 2025 | Davis John EChief Commercial Officer · O | ▼ Sale | 10,802 | $43.67 | $472K | -4.9% | — |
Every $AORT filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Artivion filings can reach your inbox instead.
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $AORT feed.